DOSE-AHF Diuretic Optimization Strategies Evaluation in Acute Heart Failure Duke Heart Failure Research Pager: 970-0736.

Slides:



Advertisements
Similar presentations
G. Michael Felker, MD, MHS, FACC Christopher M. O’Connor, MD, FACC
Advertisements

Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Adrian F. Hernandez, MD On behalf of the ASCEND-HF Committees, Investigators.
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
Girish Singhania N Engl J Med 2012 Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome.
Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.
Ian M. Carrese PA-S2 South University PA Program July 21, 2012
THE IMPORTANCE OF PUBLISHING NEGATIVE FINDINGS Rolofylline, an Adenosine A1 – Receptor Antagonist, in Acute Heart Failure Barry M. Massie et al The New.
Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
SMH DKA PROTOCOL Physician Information. Insulin Drip protocol for DKA  Purpose: Quick/Safe management of the patient in DKA  Method: Evidence based.
Introducing The SHINE Trial (Stroke Hyperglycemia Insulin Network Effort) An Overview for Clinical Nurses NIH-NINDS U01 NSO69498.
Presenters for Journal Club: James Cooper Eugenie Shieh Aaron Schueneman Tim Niessen.
Clinical Trials Medical Interventions
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Assessing Pain What is pain? Do you believe that “perception is reality”? What are EB clinical practice guidelines?? What if client non-verbal, or you.
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
Family Birth Center Performance & Quality Improvement: Labor Induction Process September 16, 2010.
Our Experiences With Natural Natural Products As Potential Therapeutic Agents : Towards Safer & Cost Effective Therapy Dr. Mrs.Chanda Kulkarni. MBBS; MD;
1 Post Marketing Plan Earl Sands, M.D. Vice President and Chief Medical Officer US Research and Development Solvay Pharmaceuticals Earl Sands, M.D. Vice.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Management of Hypertensive Emergencies. New paradigm in treatment of acute hypertension Acute vascular injury has chronic sequelae Prevention of exaggerated.
FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 1 OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M.D. On Behalf Of The Division Of Cardio-Renal Drug Products.
OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M. D
Carl Muroi, Andrej Terzic, et. Al University Hospital Zurich, Surgical Neurology 69 (2008)
Nursing Process- Implementaton. Implementation Implementation is a category of nursing behavior in which the actions necessary for accomplishing the health.
How to Participate in Research Eric Kleerup, M.D. & Donald Tashkin, M.D. David Geffen School of Medicine at UCLA Los Angeles, California.
CARRESS Cardiorenal Rescue Study in Acute Decompensated Heart Failure Duke Heart Failure Research Pager:
SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.
Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support SURVIVE-WSURVIVE-W Presented at The American Heart Association Scientific.
Binu George , Heather Bury Critical care Journal Club May 2014
Calculations.
Therapeutic Drug Monitoring (TDM) Sticker Project A New Method for Documenting Times of Medication Doses and Drug Levels.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
OASIS-2 OASIS-2 OVERVIEW 10,141 patients evaluating Hirudin vs. Heparin and 3712 patients evaluating Warfarin vs. Standard Therapy International (16 Countries)
A POST-MARKETING EVALUATION OF SAFETY CAMPTOSAR + 5-FU/LV FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER A POST-MARKETING EVALUATION OF SAFETY.
DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Clinical Trial Design Issues Phill Price MD.
RAD Immunosuppression in Heart Transplant Recipients Duke Heart Failure Research Pager:
1 Clinical Overview Omeprazole Magnesium (Prilosec 1 TM ) June 21, 2002 Mark Avigan, MD CM Division of Gastrointestinal and Coagulation Drug Products CDER,
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
ASCEND-HF Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure Duke Heart Failure Research Pager:
From: PLOS Neglected Tropical DiseaseJanuary 2014 Presented by Pavitra Charoensrisakkul and Peeraya Permkarnjaroen 3 rd year medical cadet Phramongkutklao.
ד"ר בלמור ג'ינג'י פנימית ב תל השומר
1 PATIENT SAFETY WORK PRODUCT—Created as part of LPSES - the LMHS Patient Safety Evaluation System Lee Memorial Health System Smart Pump PI Team Smart.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
Diuretic Strategies in Patients with Acute Decompensated Heart Failure
Copyright © 2007 American Medical Association. All rights reserved.
Mustafa Serinken MD, Cenker Eken MD, Kamil Tunay MD, Yalcin
Figure 2 Pain intensity over 8 hours
Intravenous Solutions, Equipment, and Calculations
Clinical Trials Medical Interventions
Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study
Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery  Srikrishna Sirivella, MD, Isaac Gielchinsky,
Volume 143, Issue 6, Pages (June 2013)
Clinical Trials.
Expert Insights on Complex Clinical Cases of Edema
Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter,
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.
Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery  Srikrishna Sirivella, MD, Isaac Gielchinsky,
MK-0954 PN948 NOT APPROVED FOR USE (date)
Heart Failure. Enhancing Myosin Activation and Cardiac Contractility: Implications for Heart Failure.
ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.
Use of Diuretics in Heart Failure: A Precarious Balance
TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)
European Heart Journal Advance Access
The Basics of Intravenous Fluid Administration
INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE
Presentation transcript:

DOSE-AHF Diuretic Optimization Strategies Evaluation in Acute Heart Failure Duke Heart Failure Research Pager:

Purpose Double blinded controlled study to evaluate safety and efficacy of high intensification diuretics vs. low intensification diuretics in Acute Decompensated Heart Failure (ADHF) and IV continuous vs. intermittent bolus q12 hours – –Double blinded study meaning subjects, MD, and research team are unaware of what treatment is being received.

Inclusion Criteria ADHF with 24 hrs of admission Potential need for IV loop diuretics for next 48hrs

Interventions Randomized to 1 of 4 combination treatments Low dose IV Furosemide by continuous infusion Low dose IV Furosemide by intermittent bolus q12 hrs High dose IV Furosemide by continuous infusion High dose IV Furosemide by intermittent bolus q12 hrs Subjects receive BOTH IV bolus q12 hrs AND continuous infusion; only one contains the active study drug Furosemide

Interventions Open label Furosemide may be used at the discretion of the physician. –If the MD feels the patient is not being diuresed effectively, additional Furosemide may be given in addition to study drug.

Nursing Roles Start at the same time: –Continuous infusion (volume of 250 ml) with a flow rate of 10 ml/hr –Bolus (volume of 50 ml) with a flow rate of 40.2 ml/hr After 12 hours: –Hang the next bolus (volume of 50 ml) with a flow rate of 40.2 ml/hr Ask patients to complete the Visual Analog Scales (VAS*): Global Well-being and Dyspnea at specific intervals: 6 hrs and 12 hrs after initiation of study drug infusion and daily for 4 days Only 1 IV line necessary; both drugs can run through same IV *Found in patient’s chart box.

Outcomes Why is this study being done? –SAFETY: Determine the change in serum creatinine from time of randomization to 72 hrs –EFFICACY: As indicated by the Global Well- being and Dyspnea Visual Analog Scales (VAS)